INT79816

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.74
First Reported 1999
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 13
Disease Relevance 8.08
Pain Relevance 2.06

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Pla2g2a) extracellular space (Pla2g2a) endoplasmic reticulum (Pla2g2a)
Anatomy Link Frequency
paw 1
platelet 1
Pla2g2a (Mus musculus)
Pain Link Frequency Relevance Heat
Potency 1 99.68 Very High Very High Very High
Inflammation 51 95.60 Very High Very High Very High
COX2 2 91.96 High High
cOX1 3 91.76 High High
allodynia 2 91.00 High High
cINOD 16 89.68 High High
cva 29 89.64 High High
cytokine 4 88.96 High High
Pain 27 87.68 High High
Eae 3 87.44 High High
Disease Link Frequency Relevance Heat
Reprotox - General 1 94 99.44 Very High Very High Very High
Hypersensitivity 71 99.28 Very High Very High Very High
Pressure And Volume Under Development 4 99.24 Very High Very High Very High
Stress 6 99.16 Very High Very High Very High
Death 27 98.72 Very High Very High Very High
Disease 102 98.48 Very High Very High Very High
Cancer 60 98.24 Very High Very High Very High
INFLAMMATION 63 95.60 Very High Very High Very High
Colon Cancer 152 95.52 Very High Very High Very High
Cv General 4 Under Development 27 93.84 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The most active interacting compound 3h from in vitro inhibition of PLA2 activity showed similar potency in the in vivo neutralization of PLA2 induced mouse paw edema and hemolytic activity.
Localization (neutralization) of PLA2 in paw associated with pressure and volume under development and potency
1) Confidence 0.74 Published 2009 Journal Chem. Pharm. Bull. Section Abstract Doc Link 19122311 Disease Relevance 0.31 Pain Relevance 0.21
In 1995, a candidate was identified, the secretory phospholipase A2 gene (sPLA2), which is believed to account for about 50% of the variation seen in Min mice [57].
Localization (secretory) of sPLA2
2) Confidence 0.62 Published 2003 Journal Hered Cancer Clin Pract Section Body Doc Link PMC2840009 Disease Relevance 0.76 Pain Relevance 0.05
The present study was carried out, using inhibitors to secretory phospholipase A2 (sPLA2, 12-epi-scalaradial), cytosolic phospholipase A2 (cPLA2, AACOCF3), or calcium-independent phospholipase A2 (iPLA2, bromoenol lactone), to compare possible contributions of central nervous PLA2 isoforms to the development of allodynia after facial carrageenan injection in mice.
Localization (secretory) of sPLA2 associated with allodynia
3) Confidence 0.53 Published 2004 Journal Pain Section Abstract Doc Link 15494195 Disease Relevance 0.17 Pain Relevance 0.23
This enzyme family is comprised of approximately 15 groups and four main types, including the secreted sPLA2, cytosolic cPLA2, calcium-independent iPLA2, and platelet activating factor (PAF) [33].
Localization (secreted) of sPLA2 in platelet
4) Confidence 0.50 Published 2010 Journal Mol Pain Section Body Doc Link PMC2831877 Disease Relevance 0.60 Pain Relevance 0.52
If released from the membranes of these cells by PLA2 under conditions of stress, PUFAs become precursors for a variety of mediators involved in the resolution of inflammation.
Localization (released) of PLA2 associated with stress and inflammation
5) Confidence 0.49 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2834569 Disease Relevance 0.64 Pain Relevance 0.22
These genes were: ACPP, ADAM2, AMACR, AMD1, ASAH1, DHCR24, FLNA, KLK3, KPNB1, PLA2G2A, RPL13A, RPL35A, RPL37A, RPL39, RPLP2, RPS20, STEAP2, and TACC (Table 4).
Localization (were) of PLA2G2A
6) Confidence 0.44 Published 2010 Journal BMC Med Genomics Section Body Doc Link PMC2956710 Disease Relevance 0.44 Pain Relevance 0
Thus, these data suggest that, in a high risk clinical scenario represented by patients with a greater prevalence of atherothrombotic risk factors, the presence of PlA2 is associated with a more aggressive disease leading to an higher incidence of major ischemic events and to an unfavourable outcome.
Localization (presence) of PlA2 associated with disease
7) Confidence 0.21 Published 2010 Journal BMC Cardiovasc Disord Section Body Doc Link PMC2954874 Disease Relevance 1.40 Pain Relevance 0.08
Cox regression analysis identified the presence of PlA2 as an independent predictor of cardiac death (OR: 9.594, 95% CI: 2.6 to 35.3, p = 0.002) and overall MACE (OR: 1.829, 95% CI: 1.054 to 3.176, p = 0.032).
Localization (presence) of PlA2 associated with death
8) Confidence 0.20 Published 2010 Journal BMC Cardiovasc Disord Section Abstract Doc Link PMC2954874 Disease Relevance 0.82 Pain Relevance 0.03
They represent independent use of PLA2 as toxins and are thus not homologous to each other as result from separate recruitment events.
Localization (use) of PLA2
9) Confidence 0.14 Published 2005 Journal Evidence-based Complementary and Alternative Medicine Section Body Doc Link PMC1062156 Disease Relevance 0.55 Pain Relevance 0.24
The dose-related decreases in EF50 were accompanied by increases in esophageal pressures.
Localization (decreases) of EF50
10) Confidence 0.11 Published 2005 Journal Respir Res Section Body Doc Link PMC1316879 Disease Relevance 0.32 Pain Relevance 0
Noninvasive determination of EF50 also showed that allergic mice were significantly more responsive to MCh, as indicated by significantly lower PD50 values for EF50 when compared with controls (P = 0.032) (Fig. 3).


Localization (determination) of EF50 associated with hypersensitivity
11) Confidence 0.11 Published 2005 Journal Respir Res Section Body Doc Link PMC1316879 Disease Relevance 0.73 Pain Relevance 0.08
The PLA2 targeted by alminoprofen is likely the secretory phospholipase A2 (sPLA2) while the COX targeted is the COX-2.
Localization (secretory) of secretory phospholipase A2
12) Confidence 0.09 Published 1999 Journal Biochem. Pharmacol. Section Abstract Doc Link 9933032 Disease Relevance 0.34 Pain Relevance 0.39
Because of its localization within the Mom-1 (Min modifier) locus, and its promotion of tumors in APCMin mice, it had first been suggested that PLA2G2A may represent a tumor suppressor gene involved in familial forms of CRC [44].
Localization (localization) of Mom-1 associated with cancer and colon cancer
13) Confidence 0.07 Published 2008 Journal BMC Cancer Section Body Doc Link PMC2585099 Disease Relevance 1.02 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox